These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 26907364

  • 1. FDG-PET/ceCT is useful to predict recurrence of Pseudomyxoma peritonei.
    Dubreuil J, Giammarile F, Rousset P, Bakrin N, Passot G, Isaac S, Glehen O, Skanjeti A.
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1630-7. PubMed ID: 26907364
    [Abstract] [Full Text] [Related]

  • 2. Impact of a modified peritoneal cancer index using FDG-PET/CT (PET-PCI) in predicting tumor grade and progression-free survival in patients with pseudomyxoma peritonei.
    Hotta M, Minamimoto R, Gohda Y, Igari T, Yano H.
    Eur Radiol; 2019 Oct; 29(10):5709-5716. PubMed ID: 30874878
    [Abstract] [Full Text] [Related]

  • 3. Pseudomyxoma peritonei: role of 18F-FDG PET in preoperative evaluation of pathological grade and potential for complete cytoreduction.
    Passot G, Glehen O, Pellet O, Isaac S, Tychyj C, Mohamed F, Giammarile F, Gilly FN, Cotte E.
    Eur J Surg Oncol; 2010 Mar; 36(3):315-23. PubMed ID: 19818580
    [Abstract] [Full Text] [Related]

  • 4. The role of 18F-FDG-PET/ceCT in peritoneal mesothelioma.
    Dubreuil J, Giammarile F, Rousset P, Rubello D, Bakrin N, Passot G, Isaac S, Glehen O, Skanjeti A.
    Nucl Med Commun; 2017 Apr; 38(4):312-318. PubMed ID: 28244976
    [Abstract] [Full Text] [Related]

  • 5. Clinical Effectiveness of Preoperative 18F-FDG PET/CT in Predicting Pathological Tumor Grade in Patients with Pseudomyxoma Peritonei Originating from Appendix: A Retrospective Cohort Study.
    Aso K, Gohda Y, Hotta M, Minamimoto R, Shimizu Y, Uemura Y, Yano H.
    Ann Surg Oncol; 2024 Mar; 31(3):1990-1995. PubMed ID: 38082170
    [Abstract] [Full Text] [Related]

  • 6. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D, Kusamura S, Nonaka D, Langer M, Andreola S, Favaro M, Gavazzi C, Laterza B, Deraco M.
    Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
    [Abstract] [Full Text] [Related]

  • 7. Correlation of Radiologic with Surgical Peritoneal Cancer Index Scores in Patients with Pseudomyxoma Peritonei and Peritoneal Carcinomatosis: How Well Can We Predict Resectability?
    Flicek K, Ashfaq A, Johnson CD, Menias C, Bagaria S, Wasif N.
    J Gastrointest Surg; 2016 Feb; 20(2):307-12. PubMed ID: 26162922
    [Abstract] [Full Text] [Related]

  • 8. Pseudomyxoma peritonei: visceral scalloping on CT is a predictor of recurrence after complete cytoreductive surgery.
    Hotta M, Minamimoto R, Gohda Y, Tajima T, Kiyomatsu T, Yano H.
    Eur Radiol; 2020 Aug; 30(8):4193-4200. PubMed ID: 32211961
    [Abstract] [Full Text] [Related]

  • 9. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
    Vaira M, Cioppa T, DE Marco G, Bing C, D'Amico S, D'Alessandro M, Fiorentini G, DE Simone M.
    In Vivo; 2009 Aug; 23(4):639-44. PubMed ID: 19567401
    [Abstract] [Full Text] [Related]

  • 10. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, Sardi A, Liauw W, Yan TD, Barrios P, Gómez Portilla A, de Hingh IH, Ceelen WP, Pelz JO, Piso P, González-Moreno S, Van Der Speeten K, Morris DL.
    J Clin Oncol; 2012 Jul 10; 30(20):2449-56. PubMed ID: 22614976
    [Abstract] [Full Text] [Related]

  • 11. [Prognostic value of clinical and pathological characteristics in 48 women with pseudomyxoma peritonei].
    Lu YY, Guo AT, Liu AJ, Shi HY.
    Zhonghua Fu Chan Ke Za Zhi; 2013 Aug 10; 48(8):595-601. PubMed ID: 24199925
    [Abstract] [Full Text] [Related]

  • 12. Diagnostic value of contrast-enhanced CT combined with 18-FDG PET in patients selected for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Sommariva A, Evangelista L, Pintacuda G, Cervino AR, Ramondo G, Rossi CR.
    Abdom Radiol (NY); 2018 May 10; 43(5):1094-1100. PubMed ID: 28770289
    [Abstract] [Full Text] [Related]

  • 13. Diagnostic performance of positron emission tomography in the staging of pseudomyxoma peritonei.
    Flood MP, Kong JC, Pham T, Waters PS, Soucisse M, Ramsay R, Wong HL, Mitchell C, Michael M, McCormick JJ, Warrier SK, Akhurst T, Heriot AG.
    Eur J Surg Oncol; 2022 Jul 10; 48(7):1606-1613. PubMed ID: 35148916
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Combined ultrasonography and CT for prognosis and predicting clinical outcomes of patients with pseudomyxoma peritonei.
    Han X, Zhang Q, Zhou N, Ma R, Wang J, Zhai X, Cui B, Lu Y, Liang L.
    Eur Radiol; 2023 Apr 10; 33(4):2800-2808. PubMed ID: 36418618
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The modified Glasgow prognosis score predicts for overall and disease-free survival following cytoreductive surgery and HIPEC in patients with pseudomyxoma peritonei of appendiceal origin.
    Tan GH, Novo CA, Dayal S, Chandrakumaran K, Mohamed F, Cecil T, Moran BJ.
    Eur J Surg Oncol; 2017 Feb 10; 43(2):388-394. PubMed ID: 27866811
    [Abstract] [Full Text] [Related]

  • 20. Value of preoperative ultrasound in evaluating the peritoneal cancer index of pseudomyxoma peritonei.
    Liang L, Wang W, Zhou N, Guo J, Lu Y, Xu H, Zhang S.
    World J Surg Oncol; 2019 Nov 12; 17(1):192. PubMed ID: 31718654
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.